These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16227561)

  • 1. Problems with botulinum toxin treatment in mitochondrial cytopathy: case report and review of the literature.
    Gioltzoglou T; Cordivari C; Lee PJ; Hanna MG; Lees AJ
    J Neurol Neurosurg Psychiatry; 2005 Nov; 76(11):1594-6. PubMed ID: 16227561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapsing-remitting severe generalized muscular weakness after botulinum toxin treatment for hyperhidrosis.
    Chiarello D; Piombo M; Corbetto M; Di Pino G; Assenza G; Capone F; Di Lazzaro V
    Muscle Nerve; 2014 Sep; 50(3):456-7. PubMed ID: 24890202
    [No Abstract]   [Full Text] [Related]  

  • 4. Botulinum Toxin A in bruxers. One year experience.
    Redaelli A
    Saudi Med J; 2011 Feb; 32(2):156-8. PubMed ID: 21301762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilateral Thyroarytenoid Botulinum Toxin Type A Injection for the Treatment of Refractory Chronic Cough.
    Sasieta HC; Iyer VN; Orbelo DM; Patton C; Pittelko R; Keogh K; Lim KG; Ekbom DC
    JAMA Otolaryngol Head Neck Surg; 2016 Sep; 142(9):881-8. PubMed ID: 27367917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of spasticity associated pain with botulinum toxin A.
    Wissel J; Müller J; Dressnandt J; Heinen F; Naumann M; Topka H; Poewe W
    J Pain Symptom Manage; 2000 Jul; 20(1):44-9. PubMed ID: 10946168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined botulinum toxin type A with modified constraint-induced movement therapy for chronic stroke patients with upper extremity spasticity: a randomized controlled study.
    Sun SF; Hsu CW; Sun HP; Hwang CW; Yang CL; Wang JL
    Neurorehabil Neural Repair; 2010 Jan; 24(1):34-41. PubMed ID: 19729582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic adverse effects after botulinum toxin type B (myobloc) injections for the treatment of palmar hyperhidrosis.
    Baumann LS; Halem ML
    Arch Dermatol; 2003 Feb; 139(2):226-7. PubMed ID: 12588237
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis.
    Meijer JW; van Kuijk AA; Geurts AC; Schelhaas HJ; Zwarts MJ
    Am J Phys Med Rehabil; 2008 Apr; 87(4):321-4. PubMed ID: 18303472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysport produces intrinsically more swallowing problems than Botox: unexpected results from a conversion factor study in cervical dystonia.
    Dressler D
    J Neurol Neurosurg Psychiatry; 2002 Nov; 73(5):604; author reply 604. PubMed ID: 12397170
    [No Abstract]   [Full Text] [Related]  

  • 11. Botulinum toxin A during pregnancy: a survey of treating physicians.
    Morgan JC; Iyer SS; Moser ET; Singer C; Sethi KD
    J Neurol Neurosurg Psychiatry; 2006 Jan; 77(1):117-9. PubMed ID: 16361610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia.
    Ansved T; Odergren T; Borg K
    Neurology; 1997 May; 48(5):1440-2. PubMed ID: 9153487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Applications of botulinum toxin in Neurology].
    Garcia-Ruiz PJ
    Med Clin (Barc); 2013 Jul; 141(1):33-6. PubMed ID: 23434466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unlabeled uses of botulinum toxins: a review, part 2.
    Cheng CM; Chen JS; Patel RP
    Am J Health Syst Pharm; 2006 Feb; 63(3):225-32. PubMed ID: 16434781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of botulinum toxin type A for chronic cough: a neuropathic model.
    Chu MW; Lieser JD; Sinacori JT
    Arch Otolaryngol Head Neck Surg; 2010 May; 136(5):447-52. PubMed ID: 20479373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyradiculoneuritis after botulinum toxin therapy for cervical dystonia.
    Burguera JA; Villaroya T; López-Alemany M
    Clin Neuropharmacol; 2000; 23(4):226-8. PubMed ID: 11020130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and self-reported efficacy of botulinum toxin for adult spasticity in current clinical practice: a prospective observational study.
    Muller F; Cugy E; Ducerf C; Delleci C; Guehl D; Joseph PA; Burbaud P; Dehail P
    Clin Rehabil; 2012 Feb; 26(2):174-9. PubMed ID: 21937525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: a case for switching therapy?
    Santamato A; Panza F; Solfrizzi V; Frisardi V; Ranieri M; Fiore P
    J Rehabil Med; 2008 Nov; 40(10):882-3. PubMed ID: 19242630
    [No Abstract]   [Full Text] [Related]  

  • 19. Pyridostigmine for the Reversal of Severe Adverse Reactions to Botulinum Toxin in Children.
    Boerner RM; Young DL; Gnagi SH; White DR; Halstead LA
    J Pediatr; 2018 Mar; 194():241-243. PubMed ID: 29275924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin type A vs type B for axillary hyperhidrosis in a case series of patients observed for 6 months.
    Frasson E; Brigo F; Acler M; Didonè G; Vicentini S; Bertolasi L
    Arch Dermatol; 2011 Jan; 147(1):122-3. PubMed ID: 21242408
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.